Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.11.20

Sai Life Sciences opens representative office in Tokyo, Japan

Sai Life Sciences opens representative office in Tokyo, Japan

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRO-CDMO), announced the opening of its representative office in Tokyo, Japan. The new office will serve as base for the company’s outreach to innovator pharmaceutical and biotech companies in Japan and other countries in the Asia Pacific region. A seasoned industry specialist, Mr. Junjiro Sato has been appointed as Representative Director to be based in Tokyo and spearhead the efforts.

Sai Life Sciences will be participating in the PharmaLab Expo Tokyo (held inside INTERPHEX Week) during Nov 25-27, 2020 to create awareness about its unique service offerings across drug discovery, development and commercialization.

Sai Life Sciences already has a significant connection with the Japanese market. It was the launch site for commercial API supplies of an NCE to Japan and has supplied over 10 tonnes of API with batch sizes of 50 Kg to 150 Kg scale over the past 4 years. It also is a supplier of registered starting materials for two other commercial APIs. From a Discovery perspective, the company has helped several biotech and pharma companies advance programs from HIT to lead optimization/ candidate stage, through its chemistry, biology and DMPK services.

Over the past two decades, Sai Life Sciences has served a diverse set of NCE development programmes, consistently delivering value based on its quality and responsiveness. It has a 100% successful track record of regulatory inspections across its R&D and manufacturing facilities from both FDA and PMDA. Today, it works with 7 of the top 10 large pharma companies, in addition to several small and mid-sized pharma & biotech companies. It has 2200 employees across its facilities in India, UK and USA.

Coinciding with its 20th anniversary in 2019, the company announced Sai Nxt, an organisation-wide initiative aimed at transforming itself into a new generation CRO-CDMO. Guided by insights and feedback from customers, it is investing over US$150M to significantly expand and upgrade its R&D and manufacturing facilities, deepen scientific capabilities, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

Share article

More News

2024.02.08

Sai Life Sciences releases its Sustainability Report 2023

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), released its Sustainability Report 2022-2023. Developed in accordance with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, the fourth edition of the Sustainability report is based on the theme ‘Steadfast on Sustainability,’ and it articulates the company’s commitment to sustainability […]
Read more

2024.02.01

Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), has expanded its DMPK capabilities. The expansion comprises the addition of 25,000 sq. ft. of state-of-the-art labs equipped with cutting-edge instrumentation enabling high-end automation. Complementing the expansion has been […]
Read more

2024.01.24

Sai Life Sciences strengthens discovery leadership

Sai Life Sciences, a leading global contract research, development, and manufacturing organization, announces the addition of two seasoned professionals to its leadership team. Dr Atul Tiwari joins as Vice President – Discovery Strategy & Business, while Dr Santosh Kulkarni takes on the role of Vice President – Medicinal Chemistry. Their wealth of experience promises to […]
Read more

2023.12.21

Sai Life Sciences wins Gold in Brandon Hall Group’s Excellence in Technology Awards

Sai Life Sciences won Gold in Brandon Hall Group’s Excellence in Technology Awards in the ‘Best Advance in Content Authoring Technology’ category. Sai Life Sciences was recognized for the use of UL Create Tool, an easy-to-use, cloud-based authoring tool from UL Solutions, for making the learning process seamless and effective for all. The company utilized […]
Read more

2023.08.21

Sai Life Silver Jubilee year

Sai Life Sciences enters its Silver Jubilee year; surpasses vision of 25 commercial molecules by 2025

Sai Life Sciences entered its Silver Jubilee year with aplomb, surpassing its vision of supporting global innovator partners in bringing 25 new medicines to market by 2025. The company crossed this milestone two years ahead of schedule and is poised to sustain this momentum on the back of a strong portfolio of molecules at various […]
Read more